Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Jun;77(12):2336–2342. doi: 10.1038/bjc.1998.388

Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy.

L M Mir 1, L F Glass 1, G Sersa 1, J Teissié 1, C Domenge 1, D Miklavcic 1, M J Jaroszeski 1, S Orlowski 1, D S Reintgen 1, Z Rudolf 1, M Belehradek 1, R Gilbert 1, M P Rols 1, J Belehradek Jr 1, J M Bachaud 1, R DeConti 1, B Stabuc 1, M Cemazar 1, P Coninx 1, R Heller 1
PMCID: PMC2150377  PMID: 9649155

Abstract

Electrochemotherapy (ECT) enhances the effectiveness of chemotherapeutic agents by administering the drug in combination with short intense electric pulses. ECT is effective because electric pulses permeabilize tumour cell membranes and allow non-permeant drugs, such as bleomycin, to enter the cells. The aim of this study was to demonstrate the anti-tumour effectiveness of ECT with bleomycin on cutaneous and subcutaneous tumours. This article summarizes results obtained in independent clinical trials performed by five cancer centres. A total of 291 cutaneous or subcutaneous tumours of basal cell carcinoma (32), malignant melanoma (142), adenocarcinoma (30) and head and neck squamous cell carcinoma (87) were treated in 50 patients. Short and intense electric pulses were applied to tumours percutaneously after intravenous or intratumour administration of bleomycin. The tumours were measured and the response to the treatment evaluated 30 days after the treatment. Objective responses were obtained in 233 (85.3%) of the 273 evaluable tumours that were treated with ECT. Clinical complete responses were achieved in 154 (56.4%) tumours, and partial responses were observed in 79 (28.9%) tumours. The application of electric pulses to the patients was safe and well tolerated. An instantaneous contraction of the underlying muscles was noticed. Minimal adverse side-effects were observed. ECT was shown to be an effective local treatment. ECT was effective regardless of the histological type of the tumour. Therefore, ECT offers an approach to the treatment of cutaneous and subcutaneous tumours in patients with minimal adverse side-effects and with a high response rate.

Full text

PDF
2336

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belehradek J., Jr, Orlowski S., Poddevin B., Paoletti C., Mir L. M. Electrochemotherapy of spontaneous mammary tumours in mice. Eur J Cancer. 1991;27(1):73–76. doi: 10.1016/0277-5379(91)90065-l. [DOI] [PubMed] [Google Scholar]
  2. Belehradek J., Jr, Orlowski S., Ramirez L. H., Pron G., Poddevin B., Mir L. M. Electropermeabilization of cells in tissues assessed by the qualitative and quantitative electroloading of bleomycin. Biochim Biophys Acta. 1994 Feb 23;1190(1):155–163. doi: 10.1016/0005-2736(94)90045-0. [DOI] [PubMed] [Google Scholar]
  3. Belehradek M., Domenge C., Luboinski B., Orlowski S., Belehradek J., Jr, Mir L. M. Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial. Cancer. 1993 Dec 15;72(12):3694–3700. doi: 10.1002/1097-0142(19931215)72:12<3694::aid-cncr2820721222>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  4. Buzaid A. C., Murren J. Chemotherapy for advanced malignant melanoma. Int J Clin Lab Res. 1992;21(3):205–209. doi: 10.1007/BF02591647. [DOI] [PubMed] [Google Scholar]
  5. Coates A. S. Systemic chemotherapy for malignant melanoma. World J Surg. 1992 Mar-Apr;16(2):277–281. doi: 10.1007/BF02071532. [DOI] [PubMed] [Google Scholar]
  6. Domenge C., Orlowski S., Luboinski B., De Baere T., Schwaab G., Belehradek J., Jr, Mir L. M. Antitumor electrochemotherapy: new advances in the clinical protocol. Cancer. 1996 Mar 1;77(5):956–963. doi: 10.1002/(sici)1097-0142(19960301)77:5<956::aid-cncr23>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  7. Heller R., Jaroszeski M. J., Glass L. F., Messina J. L., Rapaport D. P., DeConti R. C., Fenske N. A., Gilbert R. A., Mir L. M., Reintgen D. S. Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer. 1996 Mar 1;77(5):964–971. doi: 10.1002/(sici)1097-0142(19960301)77:5<964::aid-cncr24>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  8. Heller R. Treatment of cutaneous nodules using electrochemotherapy. J Fla Med Assoc. 1995 Feb;82(2):147–150. [PubMed] [Google Scholar]
  9. Mir L. M., Banoun H., Paoletti C. Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization: direct access to the cytosol. Exp Cell Res. 1988 Mar;175(1):15–25. doi: 10.1016/0014-4827(88)90251-0. [DOI] [PubMed] [Google Scholar]
  10. Mir L. M. L'électrochimiothérapie antitumorale. Bull Cancer. 1994 Sep;81(9):740–748. [PubMed] [Google Scholar]
  11. Mir L. M., Orlowski S., Belehradek J., Jr, Paoletti C. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer. 1991;27(1):68–72. doi: 10.1016/0277-5379(91)90064-k. [DOI] [PubMed] [Google Scholar]
  12. Mir L. M., Orlowski S., Poddevin B., Belehradek J., Jr Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host's defenses. Eur Cytokine Netw. 1992 May-Jun;3(3):331–334. [PubMed] [Google Scholar]
  13. Mir L. M., Roth C., Orlowski S., Quintin-Colonna F., Fradelizi D., Belehradek J., Jr, Kourilsky P. Systemic antitumor effects of electrochemotherapy combined with histoincompatible cells secreting interleukin-2. J Immunother Emphasis Tumor Immunol. 1995 Jan;17(1):30–38. doi: 10.1097/00002371-199501000-00004. [DOI] [PubMed] [Google Scholar]
  14. Mir L. M., Tounekti O., Orlowski S. Bleomycin: revival of an old drug. Gen Pharmacol. 1996 Jul;27(5):745–748. doi: 10.1016/0306-3623(95)02101-9. [DOI] [PubMed] [Google Scholar]
  15. Orlowski S., Belehradek J., Jr, Paoletti C., Mir L. M. Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol. 1988 Dec 15;37(24):4727–4733. doi: 10.1016/0006-2952(88)90344-9. [DOI] [PubMed] [Google Scholar]
  16. Orlowski S., Mir L. M. Cell electropermeabilization: a new tool for biochemical and pharmacological studies. Biochim Biophys Acta. 1993 Jun 8;1154(1):51–63. doi: 10.1016/0304-4157(93)90016-h. [DOI] [PubMed] [Google Scholar]
  17. Pron G., Belehradek J., Jr, Mir L. M. Identification of a plasma membrane protein that specifically binds bleomycin. Biochem Biophys Res Commun. 1993 Jul 15;194(1):333–337. doi: 10.1006/bbrc.1993.1824. [DOI] [PubMed] [Google Scholar]
  18. Pron G., Belehradek J., Jr, Orlowski S., Mir L. M. Involvement of membrane bleomycin-binding sites in bleomycin cytotoxicity. Biochem Pharmacol. 1994 Jul 19;48(2):301–310. doi: 10.1016/0006-2952(94)90101-5. [DOI] [PubMed] [Google Scholar]
  19. Rols M. P., Teissié J. Electropermeabilization of mammalian cells. Quantitative analysis of the phenomenon. Biophys J. 1990 Nov;58(5):1089–1098. doi: 10.1016/S0006-3495(90)82451-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Salford L. G., Persson B. R., Brun A., Ceberg C. P., Kongstad P. C., Mir L. M. A new brain tumour therapy combining bleomycin with in vivo electropermeabilization. Biochem Biophys Res Commun. 1993 Jul 30;194(2):938–943. doi: 10.1006/bbrc.1993.1911. [DOI] [PubMed] [Google Scholar]
  21. Sersa G., Cemazar M., Miklavcic D. Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res. 1995 Aug 1;55(15):3450–3455. [PubMed] [Google Scholar]
  22. Tounekti O., Pron G., Belehradek J., Jr, Mir L. M. Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res. 1993 Nov 15;53(22):5462–5469. [PubMed] [Google Scholar]
  23. Yamaguchi O., Irisawa C., Baba K., Ogihara M., Yokota T., Shiraiwa Y. Potentiation of antitumor effect of bleomycin by local electric pulses in mouse bladder tumor. Tohoku J Exp Med. 1994 Mar;172(3):291–293. doi: 10.1620/tjem.172.291. [DOI] [PubMed] [Google Scholar]
  24. Yeung R. S. Management of recurrent cutaneous melanoma. Curr Probl Cancer. 1994 May-Jun;18(3):143–186. doi: 10.1016/0147-0272(94)90011-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES